Coronavirus disease 2019: A new severe acute respiratory syndrome from Wuhan in China

Related Experiment Video

Updated: Dec 18, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.7K

Y Cao, K Cai, L Xiong

    Acta Virologica
    |June 20, 2020
    PubMed

    Insights

    A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, COVID-19, emerged in late 2019. This article reviews its history, epidemiology, and clinical aspects, proposing potential antiviral drug targets.

    Area of Science:

    • Virology
    • Epidemiology
    • Public Health

    Background:

    • The emergence of coronavirus disease 2019 (COVID-19) in Wuhan, China, in December 2019, marked a significant global health event.
    • The outbreak rapidly spread, characterized by a notable fatality rate and declared a public health emergency by the WHO.
    • Initial cases were linked to the Huanan Seafood Wholesale Market, suggesting zoonotic origins.

    Purpose of the Study:

    • To provide a comprehensive overview of COVID-19, encompassing its history, epidemiology, clinical features, diagnosis, and treatment.
    • To identify potential therapeutic targets for antiviral drugs based on virus genome sequencing and host-cell interaction models.
    • To contribute insights for epidemic control strategies and vaccine development.

    Main Methods:

    • Review of recently published studies on COVID-19.
    • Analysis of virus genome sequencing data.
    • Modeling of host cell-virus interactions.

    Main Results:

    • Identification of SARS-CoV-2 as the causative agent of COVID-19.
    • Characterization of the outbreak's epidemiology and clinical presentation.
    • Proposal of potential targets for antiviral drug development.

    Conclusions:

    • SARS-CoV-2 is the novel coronavirus responsible for the COVID-19 pandemic.
    • Understanding the virus's characteristics is crucial for effective treatment and control.
    • Further research into antiviral targets and vaccine development is essential for managing the epidemic.

    More Related Videos

    Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

    Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

    Published on: November 5, 2021

    3.2K
    Quantification and Whole Genome Characterization of SARS-CoV-2 RNA in Wastewater and Air Samples09:26

    Quantification and Whole Genome Characterization of SARS-CoV-2 RNA in Wastewater and Air Samples

    Published on: June 30, 2023

    1.5K

    Related Concept Videos

    Acute Respiratory Failure-II01:21

    Acute Respiratory Failure-II

    Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
    The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
    884
    Acute Respiratory Failure-V01:29

    Acute Respiratory Failure-V

    The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
    Ensure that patients are monitored continuously for their response to therapy, including changes in...
    351
    Acute Respiratory Failure-I01:21

    Acute Respiratory Failure-I

    Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
    Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
    675
    Acute Respiratory Failure-III01:30

    Acute Respiratory Failure-III

    Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
    627
    Single Nucleotide Polymorphisms-SNPs01:05

    Single Nucleotide Polymorphisms-SNPs

    A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
    17.7K
    Acute Coronary Syndrome I: Introduction01:30

    Acute Coronary Syndrome I: Introduction

    Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
    538